OmniStar Financial Group Inc. Acquires 2,499 Shares of Clorox Co (NYSE:CLX)

Share on StockTwits

OmniStar Financial Group Inc. raised its holdings in Clorox Co (NYSE:CLX) by 23.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,954 shares of the company’s stock after buying an additional 2,499 shares during the quarter. Clorox comprises 1.7% of OmniStar Financial Group Inc.’s investment portfolio, making the stock its 15th largest position. OmniStar Financial Group Inc.’s holdings in Clorox were worth $1,967,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Heritage Wealth Advisors bought a new stake in shares of Clorox during the second quarter valued at approximately $30,000. Transamerica Financial Advisors Inc. bought a new stake in shares of Clorox during the second quarter valued at approximately $41,000. Mirova bought a new stake in shares of Clorox during the second quarter valued at approximately $47,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Clorox by 45.9% during the third quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 334 shares of the company’s stock valued at $50,000 after purchasing an additional 105 shares in the last quarter. Finally, Prestige Wealth Management Group LLC bought a new stake in shares of Clorox during the second quarter valued at approximately $53,000. Hedge funds and other institutional investors own 78.18% of the company’s stock.

In other Clorox news, SVP Michael R. Costello sold 6,997 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $162.56, for a total value of $1,137,432.32. Following the sale, the senior vice president now directly owns 29,016 shares of the company’s stock, valued at $4,716,840.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director A D. David Mackay sold 3,400 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $154.87, for a total value of $526,558.00. The disclosure for this sale can be found here. Insiders sold 15,609 shares of company stock worth $2,497,443 over the last three months. Corporate insiders own 1.14% of the company’s stock.

Clorox stock traded down $0.50 during mid-day trading on Friday, hitting $150.25. The company had a trading volume of 35,991 shares, compared to its average volume of 1,172,253. The company has a current ratio of 0.91, a quick ratio of 0.55 and a debt-to-equity ratio of 4.09. The stock’s 50 day moving average price is $155.39 and its two-hundred day moving average price is $155.38. Clorox Co has a 12 month low of $141.53 and a 12 month high of $167.70. The company has a market capitalization of $18.79 billion, a PE ratio of 23.77, a price-to-earnings-growth ratio of 5.05 and a beta of 0.40.

Clorox (NYSE:CLX) last released its earnings results on Thursday, August 1st. The company reported $1.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.84 by $0.04. Clorox had a return on equity of 118.88% and a net margin of 13.20%. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.69 billion. During the same period in the previous year, the company posted $1.66 earnings per share. The company’s revenue for the quarter was down 3.8% compared to the same quarter last year. Equities research analysts anticipate that Clorox Co will post 6.14 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Wednesday, October 30th will be issued a $1.06 dividend. This represents a $4.24 annualized dividend and a yield of 2.82%. The ex-dividend date is Tuesday, October 29th. Clorox’s dividend payout ratio (DPR) is 67.09%.

Several equities research analysts recently weighed in on the company. UBS Group dropped their price target on Clorox from $128.00 to $125.00 and set a “sell” rating on the stock in a research report on Thursday, October 3rd. ValuEngine lowered Clorox from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Morgan Stanley restated an “underweight” rating and set a $134.00 price target (down from $144.00) on shares of Clorox in a research report on Monday, September 30th. Citigroup dropped their price target on Clorox from $167.00 to $163.00 and set a “neutral” rating on the stock in a research report on Thursday, October 3rd. Finally, Bank of America dropped their price target on Clorox from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, October 3rd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the stock. Clorox presently has a consensus rating of “Hold” and a consensus price target of $152.25.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Story: Cash Flow

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.